Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 5.73B +163.8% |
| Revenue (ttm) | 569.61M +50.2% |
| Net Income | -798.84M |
| EPS | -15.17 |
| Shares Out | 60.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 471,823 |
| Open | 95.44 |
| Previous Close | 95.48 |
| Day's Range | 93.81 - 98.77 |
| 52-Week Range | 47.15 - 114.99 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 144.93 (+54.18%) |
| Earnings Date | May 6, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $144.93, which is an increase of 54.18% from the latest price.
News
Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossif...
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026.
Mirum Pharmaceuticals initiated with a Buy at Citi
Citi initiated coverage of Mirum Pharmaceuticals (MIRM) with a Buy rating and $145 price target The company’s three approved rare disease products products bring a growing revenue stream to fund…
Mirum announces new data from its rare liver disease programs at EASL
Mirum Pharmaceuticals (MIRM) announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b Vistas study of volixibat in PSC and Phase 2b AZURE-1 study of…
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Strong clinical and commercial momentum continues, with LIVMARLI sales growth, positive pivotal data in PSC, and pipeline expansion through disciplined BD. Upcoming milestones include key readouts for volixibat and Brelovitug, with significant market opportunities projected.
Mirum Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The event highlighted robust growth, a diversified rare disease pipeline, and strategic capital allocation. Key assets like LIVMARLI, volixibat, and brelovitug are expected to drive significant revenue, with multiple clinical readouts and regulatory milestones anticipated in the next year.
Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Mirum Pharmaceuticals (MIRM) with an Outperform rating and $145 price target The stock has rallied over the past year by more than 100%, notes the…
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes.
Mirum Pharmaceuticals announces $600M convertible senior notes offering
Mirum Pharmaceuticals (MIRM) announced its intention to offer, subject to market conditions and other factors, $600M aggregate principal amount of convertible senior notes due 2032 in a private placem...
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Raymond James analyst Ryan Deschner raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $165 from $164 and keeps a Strong Buy rating on the shares. Published first on…
Mirum Pharmaceuticals price target raised to $145 from $125 at TD Cowen
TD Cowen raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $145 from $125 and keeps a Buy rating on the shares. The firm updated its model following its…
Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital
RBC Capital analyst Joe Kim raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $142 from $128 and keeps an Outperform rating on the shares. The company’s Q1 earnings…
Mirum Pharmaceuticals price target raised to $129 from $112 at Baird
Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $129 from $112 and keeps an Outperform rating on the shares. The firm updated its model following beat and…
Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel
Stifel raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $136 from $130 and keeps a Buy rating on the shares.
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $138 from $135 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $185 from $175 and keeps a Buy rating on the shares post the Q1 report. The company disclosed…
Mirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)
Reports Q1 revenue $159.9M, consensus $148.2M. “2026 is off to an excellent start, driven by strong commercial momentum, the recent VISTAS and AZURE-1 topline results, disciplined clinical execution, ...
Mirum Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 net product sales rose to $160M, driven by strong LIVMARLI uptake in PFIC and international markets. Full-year guidance increased to $660–$680M, with pipeline expansion into PSC, hepatitis delta, and FOP. Bluejay acquisition and Incyte licensing support future growth.
Mirum Pharmaceuticals Earnings release: Q1 2026
Mirum Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Mirum Pharmaceuticals Quarterly report: Q1 2026
Mirum Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.